Decree of the Rector n. 168 of 22/02/2024
Competition for awarding 1 research grant at the University of Udine

DISCLAIMER:
The official and legally binding call for applications is in Italian only. This document cannot be used for legal purposes and is only meant to provide information in English on the call for applications (Decree of the Rector n. 168 of 22/02/2024). Please refer to the official call published on: https://www.uniud.it/it/albo-ufficiale

Any change and integration will be made available on the above mentioned web page. Therefore, no personal written communication regarding the examination date and/or competition results shall be provided to applicants.

Annex 1

Competition announcement for the assignment of 1 research grant at the University of Udine, entitled “Study support activities with the advanced cellular drug aHyC at the interregional level - IMMUNOCLUSTER-2” SSD: MED/05 (principal investigator, Francesco Curcio)

Art. 1
A selection procedure is hereby launched for the award of 1 research grant at the University of Udine, as identified in Attachment A which constitutes an integral part of the present announcement. The research grant is linked to the research project and is subject and conditioned upon the relative funding. The fellowship may be renewed, in compliance with Art. 22, Law No. 240 of 30 December 2010 (as in the text in force before the implementation of the Conversion Law of the D.L. 36/2022, L. 79/2022), Law No. 11 of 27 February 2015, and the current regulations of the University of Udine for awarding research grants, issued with the Rector’s Decree No. 182 of 31 March 2021. The renewal is subject to the scientific coordinator’s positive assessment of the researcher’s activities, an adequate scientific rationale, and a corresponding financial covering.

The research fellowship does not give rise to any right with regards to accessing University posts.

Any personal communication to candidates related to this selection will be sent exclusively to the email address indicated when registering for the selection, as mentioned in Art. 5.

Art. 2
The research grant described in this competition announcement and the required qualifications to apply for the position are identified in Attachment A. The lack of the admission requirements leads to the automatic exclusion from the competition procedure.

Possession of a PhD or equivalent degree obtained abroad or, only for the interested areas, of a medical specialization accompanied by an adequate scientific production, constitutes a preferential qualification for awarding the research fellowship of this selection, if it has not been provided as a mandatory requirement.

Candidates in possession of a specialization qualification in the medical area obtained abroad must also attach the recognition decrees issued by the Italian Ministry of Health in order to avail themselves of the qualification of specialist doctor and of the title of surgeon. These recognition decrees are also required if the qualification has already been recognized in another country of the European Union. http://www.salute.gov.it/ProfessioniSanitariePubblico/
For the only purpose of the admission to the competition, the Examining Board (Art. 7) shall assess the equivalence of the qualification obtained abroad, except for the evaluation of the medical specialization qualification to which Article 38 of the Legislative Decree 165/2001 and subsequent modifications and additions, and EU regulations on the matter, shall be applied.

The Examining Board will proceed to the evaluation of the qualification obtained abroad according to the documentation attached to the application form. The Examining Board may exclude the candidate if the submitted documentation does not provide sufficient information for the assessment. Therefore, applicants must enclose all the documentation in their possession relating to their qualification in order to provide the Examining Board with sufficient information for assessment.

Candidates holding a qualification issued by a **European Research Area country**, if successful, must submit, if not already attached to the application form one of the following options:
- Supplement Diploma in English issued by the competent University.
- CIMEA Certificate of comparability of the foreign qualification, issued by CIMEA (Information Centre on Academic Mobility and Equivalence) via the "diplome" service at [https://cimea.diplo-me.eu/udine/#/auth/login](https://cimea.diplo-me.eu/udine/#/auth/login)

Candidates holding a qualification issued by a **non-European Research Area country**, if successful, must submit, if not already attached to the application form one of the following options:
- Declaration of the on-site value of the qualification and the certificate relating to the degree with examinations and grades. A certificate in a language other than Italian or English must be accompanied by an official translation into one of these languages (certified by the competent diplomatic-consular authority or certified by a court in Italy).
- CIMEA Certificate of comparability of the foreign qualification, issued by CIMEA (Information Centre on Academic Mobility and Equivalence) via the "diplome" service at [https://cimea.diplo-me.eu/udine/#/auth/login](https://cimea.diplo-me.eu/udine/#/auth/login)

If the Supplement Diploma or the statement/attestation of comparability are not available when signing the contract, the applicant must demonstrate that he/she has requested the documentation and submit it as soon as possible.

Any exclusion from the selection procedure due to lack of eligibility requirements, absence of required documents, failure to sign the selection application or submission of the selection application in a manner different from what is provided for in this call for applications will be communicated to applicants exclusively at the email address indicated in the application form.

**Art. 3**

The research grant referred to in this call for applications cannot be awarded:

a. to employees of Universities and the entities referred to in Article 22, section 1, of Italian Law no. 240 of 30 December 2010 (in the text prior to the reform introduced by Law no. 79 of 29 June 2022);

b. to those who have already been awarded research grants pursuant to Italian Law no. 240 of 30 December 2010 (prior to the reform introduced by Law no. 79 of 29 June 2022) for the maximum period provided by law, even if not continuously, excluding the period in which the grant was used in conjunction with the doctorate, up to the legal term of the relative course;

c. to those who have already benefited from research grants and fixed-term researcher contracts provided for, respectively, in Articles 22 and 24 of Italian Law no. 240 of 30 December 2010 (in the text prior to the reform introduced by Law no. 79 of 29 June 2022), for a total of 12 years, even if not consecutive;

d. to anyone who has a degree of kinship or affinity, up to and including the fourth degree, with:
   - the Rector, the Director General or a member of the Board of Directors of the University of Udine;
   - the scientific supervisor or a professor/researcher belonging to the department or organisation hosting the research grant in question.

**RESEARCH SERVICES AREA**
Research Training Office
Department Head: Sandra Salvador
Procedure Supervisor: Sandra Salvador
Procedure Compiler: Francesca Mion
The research grant provided for in this call for applications cannot be combined:

a) with scholarships of any kind, except for those granted by Italian or foreign institutions to supplement, by means of stays abroad, the fellow’s training or research activities;
b) with other research grants;
c) with an employment relationship, even if part-time, without prejudice to the relevant provisions for employees of public administrations.

The grant awarded under this call for applications is also incompatible with simultaneous attendance at university degree courses, either Bachelor’s degree or Master’s degree courses, research Doctorates with scholarships and medical specializations, in Italy or abroad.

Art. 4

Applicants must enclose with their application, under penalty of exclusion, the following documents:

a) their professional scientific CV, highlighting the candidate's aptitude for carrying out and implementing the research project (Attachment A);
b) their identity card, their passport or any other identification document;
c) (for candidates with a foreign qualification only) certification or self-certification of both the academic qualification required for the admission to the selection, and of the exams (with evaluation) took during the period of study abroad, and of any other document that can be useful to the evaluation of the degree by the Examining Board.

Applicants can attach to the application, publications and any other certification considered useful to demonstrate the qualification based on the research program (Attachment A) and to certify any research activity accomplished at public or private institutes (indicating the starting and ending date and the duration).

The documents and qualifications mentioned above must be submitted in Italian or English. Those that are not as requested will not be evaluated. Documents originally written in a language other than Italian or English must come with a translation in Italian or English, that the candidate will do on its own responsibility. The translation can be an abstract concerning the thesis.

Italian and Community candidates wishing to submit qualifications referring to conditions and facts attested by Public Administrations must proceed exclusively with self-certification.

Non-EU citizens legally residing in Italy may self-certify only data that can be verified or certified by Italian public bodies. They may also use declarations in lieu when provided for by an international convention between Italy and the declarant's country of origin.

Non-EU citizens not residing in Italy cannot self-certify.

Only the qualifications possessed by the candidate on the date the application form is submitted and submitted in accordance with the procedures set out in Article 5 will be assessed.

Failure to submit mandatory documents provided for in this article will constitute grounds for exclusion from the selection.

Art. 5

The submission of the applications for the present call starts on March 1, 2024 at 2:00 pm (Italian time) and ends on March 14, 2024 at 2:00 pm (Italian time).

The application to take part in the selection must be completed, under penalty of exclusion, using the appropriate online procedure, available at the link https://pica.cineca.it/.

1 Please be aware that the residence permit is not an identification document.
The procedure involves an applicant registration step, for those who do not already have an account, and then an application completion step.

Once completed, the online application must be signed in the manner described in the online procedure (manual signature with attached identity document or digital signature), under penalty of exclusion from selection. The application does not have to be signed if you access the above-mentioned online procedure using your SPID ID.

The qualifications referred to in Article 4 must be attached to the application in .pdf format. Individual .pdf files may not exceed 30MB.

The application for participation in the selection is automatically sent to the University of Udine with the definitive closing of the online procedure.

The University Administration:
- is not responsible if it is impossible to read the submitted documentation in electronic format due to damaged files;
- shall not accept or take into consideration qualifications or documents received in paper form or by any means other than what is specified in this article.

Reference to documents or publications already submitted in connection with other competitions is not allowed.

The Administration is not responsible for any missing document or communication because of inaccurate indication of residence and/or address submitted by the candidate during the application. Also, the Administration is not responsible if the candidate has not communicated changes in this information, or has communicated them too late. The Administration is also not responsible for any postal or telegraphic problems not attributable to the Administration itself.

Applicants are advised not to wait until the last few days before the closing date to submit their application. The University accepts no responsibility for any malfunctions due to technical problems and/or overloading of the communication line and/or application systems.

Art. 6
The test procedure is held in accordance with the modality indicated in Attachment A.

The test will aim to assess the general preparation, experience and aptitude for research of the candidate. It will consist in the evaluation of the professional scientific curriculum, of the publications and qualifications presented, and of the interview, where foreseen.

Art. 7
The examining board for the competition is identified in Attachment A of the present competition announcement, of which it is an integral part.

At its first meeting, the examining board shall appoint its President and Secretary, and establish the criteria and methods for evaluating the qualifications and the interview, where foreseen.

The results of the qualifications assessment must be disclosed to applicants during the interview, where foreseen.

The examining board can award a maximum of 100 points (one hundred out of one hundred) to the selection.

At the end of the evaluation procedure, the examining board shall formulate the general merit list based on the overall score of each candidate, and draw up the minutes of the whole competition procedure.
Based on the ranking list, the assignment is awarded to candidates who have obtained a minimum overall score of 70/100 (seventy out of one hundred).

The Examining board's judgement is final.

The ranking list will be made public exclusively through publication on the University's official website.

Applicants will not be notified of the outcome of the evaluation.

Those who do not declare their acceptance of the research grant and do not present themselves at the research centre within the deadline communicated by the latter, even if not formally, shall lose the right to receive it. Exceptions to this term will only be granted in cases of documented force majeure.

The selected candidate will have to undergo any health assessment deemed necessary by the competent doctor and aimed at issuing the assessment of suitability for the specific task according to the protocol of the host structure. The signature of the contract will be possible only after obtaining the judgment of suitability for the specific task by the Azienda Sanitaria Universitaria Friuli Centrale (ASU FC). Before signature of the research grant contract, the candidate awarded of reference research grant must submit a copy of the vaccination booklet or related certificate, and intradermal reaction – sec. Mantoux (performed in the last 12 months).

Art. 8

The research activity cannot be started before signing the contract defining the terms and conditions of the collaboration.

The activity covered by the research grant must have the following characteristics:

a) it must be carried out as part of the research programme covered by the grant and not be a merely technical support to it;
b) it must have a close connection with the realization of the research program for which the winner of the grant has been awarded the contract;
c) it must be continuous and, in any case, temporally defined, not merely occasional, and in coordination with the overall activity of the University;
d) it must be carried out autonomously, solely within the limits of the programme prepared by the programme supervisor, without predetermined working hours.

The researcher is required to submit a detailed written report on the work carried out and the results achieved, accompanied by the opinion of the scientific supervisor, to the reference organisation at the intervals set out in the contract. The researcher must also submit interim reports and timesheets, if requested by the reference organisation.

Either the fellow or the reference organisation may withdraw from the contract.

The reference organisation may terminate the contract not only in the cases referred to in Article 9, sections 2 and 3, of the "Internal rules for awarding research grants pursuant to law 240 of 30 December 2010" of the University of Udine, but also in the event the research project and therefore the financial coverage on which the research grant is based cease to exist.

With regard to accident insurance and third-party liability, the provisions of art. 3 c. 5 of the "Internal rules for awarding research grants pursuant to Italian Law no. 240 of 30 December 2010" of the University of Udine, issued by Rector's Decree no. 182 of 31 March 2021, are applied.

The Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), by authorizing with a subsequent deed the access of the selected candidate to its facilities, ensures insurance cover for professional risks and third-party liability in the course of the authorized activity. The insurance policy for accidents and occupational diseases remains at the expense of the selected candidate. In the absence of such policy, the selected candidate will not be allowed to
access the facilities of the Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), and it will not be possible to proceed with the signature of the contract.

Art. 9
The following legal dispositions shall apply to the grant referred to in this call for applications:
- for tax matters, the provisions of Article 4 of Italian Law no. 476 of 13 August 1984, as subsequently amended and supplemented;
- for social security matters, the provisions of Article 2(26) et seq. of Italian Law no. 335 of 8 August 1995, as subsequently amended and supplemented;
- for mandatory maternity leave, the provisions of the Italian Ministerial Decree of 12 July 2007;
- with regard to sick leave, the provisions of Article 1(788) of Italian Law no. 296 of 27 December 2006 and subsequent amendments.

During the period of mandatory maternity leave, the allowance paid by INPS according to Art. 5 of the Italian Ministerial Decree of 12 July 2007 is supplemented by the University up to the full amount of the research grant.

The grant will be paid in monthly instalments.

Art. 10
The data collected as part of the procedure referred to in Art. 5 are necessary to properly manage the selection procedure, for any subsequent management of the research grant and for purposes related to managing services provided by the University. The University of Udine is the Data Controller. At any time, the data subject may request access, rectification and, depending on the University's institutional purposes, cancellation and restriction of processing or oppose the processing of their data. The data subject can always lodge a complaint with the Italian Data Protection Authority. The complete disclosure is available on the University of Udine website in the “Privacy” section, accessible from the home page www.uniud.it Direct Link: https://www.uniud.it/it/pagine-speciali/guida/privacy

Art. 11
For all matters not expressly mentioned in this call for applications, refer to the regulations in force on the subject cited in the introduction and to the "Internal rules for awarding research grants pursuant to Italian Law no. 240 of 30 December 2010" of the University of Udine, issued by Rector's Decree no. 182 of 31 March 2021.

Art. 12
The procedure supervisor is Dr Sandra Salvador, Head of the Research Services Area of the University of Udine.
The Responsible office at the University of Udine is “Area Servizi per la Ricerca - Ufficio Formazione per la Ricerca”, via Mantica n. 31 - 33100 Udine, Italia.

To request information about the call for applications, please complete the following form available on the University of Udine website:
https://helpdesk.uniud.it/SubmitSR.jsp?type=req&accountId=universityofudine&populateSR_id=42105
Responsabile scientifico della ricerca / Principal investigator:

Nome e cognome / Name and surname: Francesco Curcio
Qualifica / Position: Professore Ordinario / Full Professor
Dipartimento / Department: Medicina (DMED) / Medicine
Area MUR / Research field: 06 – Scienze Mediche
Settore concorsuale e Settore scientifico disciplinare / Scientific sector: 06/A2; MED/05 – Patologia clinica

Titolo dell’assegno di ricerca / Topic of the research fellowship “assegno di ricerca”:

Testo in italiano:
Attività di supporto allo studio con il farmaco cellulare avanzato aHyC a livello interregionale – IMMUNOCLUSTER-2.

Testo in English:
Study support activities with the advanced cellular drug aHyC at the interregional level - IMMUNOCLUSTER-2.

Obiettivi previsti e risultati attesi del programma di ricerca in cui si colloca l’attività dell’assegno di ricerca / Foreseen objectives and results of the research programme performed by the research fellow “assegno di ricerca”:

Testo in italiano:
Lo sviluppo di farmaci, siano essi piccole molecole, prodotti biologici o prodotti medicinali per terapie avanzate (Advanced Therapy Medicinal Products, ATMP) è soggetto al controllo da parte delle agenzie nazionali per i farmaci e i dispositivi medici, al fine di garantire tre proprietà fondamentali per i farmaci: sicurezza, efficienza e qualità. Il partner principale, Celica Biomedical, ha una vasta esperienza nello sviluppo di farmaci cellulari avanzati in collaborazione con le istituzioni regolatorie. Il responsabile di Celica Biomedical è stato anche membro della commissione CAT (Committee for Advanced Therapies, EMA, European Medicine's Agency, Londra) nel periodo 2009-2011. Celica Biomedical ha condotto con successo uno studio clinico sul trattamento del carcinoma prostatico resistente alla castrazione mediante immunoibridomi aHyC (Chowdhury et al., 2021 Clin Transl Med). JAZMP, Agenzia pubblica per i medicinali e i dispositivi medici della Repubblica di Slovenia (parte di EMA), ha fornito l'autorizzazione per la preparazione dell'aHyC secondo una procedura certificate GMP. aHyC è già utilizzato per il trattamento di pazienti affetti da carcinoma della prostata resistenti alla castrazione nella Repubblica di Slovenia.

Nel progetto IMMUNOCLUSTER-2 verranno utilizzate anche capacità e competenze gestionali nello sviluppo di farmaci cellulari avanzati, in particolare adottando il sistema di gestione della qualità secondo lo standard ISO/SIST 17025, che è supervisionato dalle istituzioni di accreditamento slovene e da JAZMP. Il sistema di gestione della qualità si basa su una strategia che tiene conto dei rischi e dei benefici, che è anche alla base del sistema di gestione degli studi clinici. Qui sono importanti diverse linee guida, che verranno seguite per assicurare la efficace gestione del progetto, come, ad esempio, l'adozione di una struttura gerarchicamente organizzata per le attività operative, con compiti e responsabilità chiaramente definiti per ciascun addetto, l'identificazione dei rischi e la predisposizione di misure preventive, e la comunicazione accurata e tempestiva con le istituzioni e tra i partner.

Gli obiettivi generali del progetto si basano sulla cooperazione interregionale e transfrontaliera di due aziende che combinano i rispettivi prodotti innovativi, e sulla cooperazione tra istituzioni pubbliche che operano sui rispettivi lati del confine. Tale collaborazione a livello di ecosistema è necessaria, poiché sia l'obiettivo generale del progetto,
La parte italiana del progetto comprende l’Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC, PP5, “taker”) di Udine, che predisporrà una piattaforma per includere nello studio clinico pazienti con TNBC provenienti dall'Italia, e l'Università degli Studi di Udine (UNIUD, PP4), che parteciperà fornendo supporto scientifico e allo stesso tempo provvederà alla diffusione dei risultati del progetto. Inoltre, il progetto e il gruppo di lavoro sulla costituzione di una piattaforma interregionale (DP4) saranno presentati ad AIFA (Agenzia Nazionale del Farmaco) e saranno identificati i requisiti e le condizioni per l'inclusione transfrontaliera di pazienti con TNBC in uno studio clinico in cui il vaccino a cellule aHyC sarà somministrato dall'altra parte del confine. I requisiti e le condizioni individuate non solo rispetteranno la legislazione nazionale ed europea in materia di medicinali ma terranno anche conto delle linee guida e dell'obiettivo della strategia dell'UE per la regione alpina (EUSALP): migliorare la cooperazione e il coordinamento dell’azione nell'area alpina, che detta la necessità di superare non solo i confini nazionali, ma anche settoriali, per consentire una riflessione più strategica e fantasiosa sulle opportunità disponibili.

Il vincitore della selezione si occuperà di fornire supporto a tutte le attività relative alla costituzione di una piattaforma a supporto dell'inclusione di pazienti dall'Italia nello studio clinico.

**Text in English:**

The development of drugs, whether small molecules, biologics, or Advanced Therapy medicinal products (ATMPs) is subject to scrutiny by national drug and medical device agencies to ensure three fundamental properties for Drugs: first, that safety, efficiency, and quality of treatment are ensured. The lead partner has extensive experience in developing advanced cellular drugs in collaboration with regulatory institutions. The head of LP1 was also a member of the CAT committee (Committee for Advanced Therapies, EMA, European Medicine's Agency, London) during 2009-2011. LP1 conducted a successful clinical trial on the treatment of castration-resistant prostate cancer using aHyC immunohybridomas (Chowdhury et al., 2021 Clin Transl Med). JAZMP, Public Agency for Medicines and Medical Devices of the Republic of Slovenia (part of EMA), has provided approval for the preparation of aHyC according to a GMP-certified procedure. aHyC is already used for the treatment of patients with castration-resistant prostate cancer in the Republic of Slovenia.

Management skills and competencies in advanced cellular drug development will also be used in the IMMUNOCLUSTER-2 project, in particular by adopting the quality management system according to the ISO/SIST 17025 standard, which is overseen by Slovenian accreditation institutions and JAZMP. The quality management system is based on a strategy that considers risks and benefits, which is also the basis of the clinical trial management system. Several guidelines are important here, which will be followed to ensure the effective management of the project, such as, for example, the adoption of a hierarchically organized structure for operational activities, with clearly defined tasks and responsibilities for each person in charge, the identification of risks and the provision of preventive measures, and accurate and timely communication with institutions and among partners.

The overall objectives of the project are based on the interregional and cross-border cooperation of two companies combining their respective innovative products, and cooperation between public institutions operating on the respective sides of the border. Such collaboration at the ecosystem level is necessary because both the overall project goal, i.e., to initiate a cross-border clinical trial for the treatment of triple-negative breast cancer (TNBC) with a hybridoma cell-based vaccine (aHyC) at the cross-border level, that the specific objectives of the project, namely synchronization of procedures to increase immunohybridoma production in a GMP environment and the introduction of an interregional platform for the possibility of including patients in a cross-border level clinical trial, transcend national activities and the borders between the two countries. The Italian part of the project includes the Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC, PP5, "taker") in Udine, which will set up a platform to include patients with TNBC from Italy in the clinical trial, and the University of Udine (UNIUD, PP4),
which will participate by providing scientific support and at the same time provide for the dissemination of the project results. In addition, the project and the working group on the establishment of an interregional platform (DP4) will be presented to AIFA (Agenzia Nazionale del Farmaco), and requirements and conditions will be identified for cross-border inclusion of patients with TNBC in a clinical trial in which the aHyC cell vaccine will be administered on the other side of the border. The requirements and conditions identified will not only comply with national and European drug legislation but will also take into account the guidelines and objective of the EU Strategy for the Alpine Region (EUSALP): to improve cooperation and coordination of action in the Alpine area, which dictates the need to transcend not only national, but also sectoral borders, to allow for more strategic and imaginative thinking about the opportunities available.

The winner of the selection will be responsible for providing support for all activities related to the establishment of a platform to support the inclusion of patients from Italy in the clinical trial.

**Struttura dell'Università di Udine presso la quale verrà sviluppata l'attività di ricerca / Department or other structure of the University of Udine where research activities will be carried out:**

Dipartimento di Medicina / Department of Medicine

**Tipologia di attività assistenziale prevista in relazione alle esigenze del programma di ricerca / Type of care activity scheduled in relation to the needs of the research program:**

- Nessun contatto con pazienti ma solo con dati clinici sensibili. / No contact with patients but only with sensitive clinical data.
- Attività di laboratorio diagnostico senza finalità assistenziale. / Diagnostic laboratory activity without assistance purposes.

**Struttura ospedaliera coinvolta / Hospital facility involved:**

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) SOC Patologia Clinica.

**Importo dell’assegno di ricerca (al lordo oneri carico assegnista) / Total grant gross for the research fellowship:**

€ 35,212.95

**Durata dell’assegno di ricerca / Duration of the research fellowship “assegno di ricerca”:**

17 mesi / months

**Finanziamento / Financed by:**


**Requisiti di ammissione / Minimum qualifications necessary:**

- Possesso di un diploma di laurea vecchio ordinamento (ante decreto 3 novembre 1999 n. 509) o di laurea specialistica/magistrale (ex decreto 3 novembre 1999 n. 509 e decreto 22 ottobre 2004 n. 270) o titolo equivalente conseguito all’estero;
- Diploma di specializzazione in area medica con adeguata produzione scientifica;
- possesso di un curriculum scientifico professionale idoneo allo svolgimento dell’attività di ricerca contemplata.
- University degree obtained before Decree n. 509 of 3 November 1999 or specialistic/Master’s degree (post decree n. 509 of 3 November 1999 and decree n. 270 of 22 October 2004) or equivalent degree obtained abroad;
- Medical specialization accompanied by an adequate scientific production or equivalent title obtained abroad;
- professional scientific curriculum suitable for the research activity above mentioned.

Procedura selettiva / Competition procedure:
Valutazione per soli titoli. / Assessment of qualifications only.

Commissione giudicatrice / Examining Board:

<table>
<thead>
<tr>
<th>Nome e Cognome</th>
<th>Qualifica</th>
<th>SSD</th>
<th>Università</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Membri Effettivi / Permanent members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francesco Curcio</td>
<td>PO</td>
<td>MED/05</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Antonio Paolo Beltrami</td>
<td>PA</td>
<td>MED/05</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Martina Fabris</td>
<td>PA</td>
<td>MED/05</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td><strong>Membri Supplenti / Temporary members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carlo Ennio Michele Pucillo</td>
<td>PO</td>
<td>MED/04</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Daniela Cesselli</td>
<td>PA</td>
<td>MED/08</td>
<td>Università degli Studi di Udine</td>
</tr>
</tbody>
</table>